We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission (CAPYBARA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05479058
Recruitment Status : Recruiting
First Posted : July 29, 2022
Last Update Posted : March 20, 2023
Sponsor:
Information provided by (Responsible Party):
Galapagos NV

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Participants who are in clinical remission on 200 mg filgotinib once daily (q.d.) for at least 2 consecutive quarterly visits in the ongoing SELECTION-LTE study (GS-US-418-3899, NCT02914535), are planned to be rolled over and randomized in this study. The primary objective of this study is to evaluate the efficacy of filgotinib in participants in stable clinical remission on 200 mg filgotinib q.d. for whom the dose was decreased to 100 mg q.d. compared to participants remaining on 200 mg q.d.

Condition or disease Intervention/treatment Phase
Ulcerative Colitis Drug: Filgotinib Drug: Placebo Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: The study is double-blinded to treatment assignment until the last subject has reached the primary analysis time point.
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of Dose De-escalation of Orally Administered Filgotinib in Subjects With Ulcerative Colitis in Clinical Remission
Actual Study Start Date : July 26, 2022
Estimated Primary Completion Date : June 2024
Estimated Study Completion Date : November 2026

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Filgotinib 200 mg

Participants will receive filgotinib 200 mg and placebo to match filgotinib 100 mg. Participants will receive blinded treatment until primary analysis time point (after last participant completes Week 48 post baseline visit or has completed Week 12 post re-escalation visit, or after last follow-up of participant who discontinues prior to Week 48, whichever comes last), with exception of participants with endoscopic score (ES)-confirmed UC flare who will be switched to open-label 200 mg filgotinib q.d. for at least 12 weeks and may continue treatment in case of response until the end of the study.

Participants, who are blinded at the time of the primary analysis time point, will receive open-label filgotinib 200 mg q.d.

The maximum duration of the treatment will be 216 weeks.

 Drug: Filgotinib
Tablets administered orally once daily
Other Names:
  • GS-6034
  • GLPG0634

Drug: Placebo
Tablets administered orally once daily
Experimental: Filgotinib 100 mg

Participants will receive filgotinib 100 mg and placebo to match filgotinib 200 mg. Participants will receive blinded treatment until primary analysis time point (after last participant completes Week 48 post baseline visit or has completed Week 12 post re-escalation visit, or after last follow-up of participant who discontinues prior to Week 48, whichever comes last), with exception of participants with ES-confirmed UC flare who will be switched to open-label 200 mg filgotinib q.d. for at least 12 weeks and may continue treatment in case of response until the end of the study.

Participants, who are blinded at the time of the primary analysis time point, will receive open-label filgotinib 100 mg q.d.

The maximum duration of the treatment will be 216 weeks.

 Drug: Filgotinib
Tablets administered orally once daily
Other Names:
  • GS-6034
  • GLPG0634

Drug: Placebo
Tablets administered orally once daily


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percentage of Participants in Corticosteroid-free Clinical Remission Based on Modified Mayo Clinical Score (mMCS) at Week 48 [ Time Frame: Week 48 ]
    mMCS score is composed of subscores from rectal bleeding, stool frequency, and endoscopic findings (the range of each subscore is 0 to 3 with higher score indicating severe disease). mMCS remission is defined as mMCS score ≤2, with endoscopic subscore of ≤1, stool frequency subscore of ≤1, and a rectal bleeding subscore of 0.


Secondary Outcome Measures :
  1. Time to Patient-Reported Outcome Based on 2 Items (PRO2) Flare [ Time Frame: Baseline (Day 1) up to 216 weeks ]
    PRO2 includes items of stool frequency and rectal bleeding. The range of each item score is 0 to 3 with higher score indicating severe disease. PRO2 flare is defined as a PRO2 score worsening of at least 2 points and an absolute PRO2 score of at least 3, with stool frequency subscore ≥2, and rectal bleeding subscore ≥1.

  2. Time to ES-Confirmed UC Flare [ Time Frame: Baseline (Day 1) up to 216 weeks ]
    An ES-confirmed UC flare is defined as an increase in rectal bleeding subscore by at least 1 point and an increase in stool frequency subscore by at least 2 points and an increase in endoscopic subscore by at least 1 point. The range of each item score is 0 to 3 with higher score indicating severe disease.

  3. Change From Baseline in C-Reactive Protein (CRP) up to Week 48 [ Time Frame: Baseline, up to Week 48 ]
  4. Change From Baseline in Fecal Calprotectin (FCP) up to Week 48 [ Time Frame: Baseline, up to Week 48 ]
  5. Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) at Week 48 [ Time Frame: Baseline, Week 48 ]
    IBDQ consists of 32 questions divided into four dimensions: bowel symptoms (10 items), systemic symptoms (5 items), emotional function (12 items), and social function (5 items). Every question has graded responses from 1 (worst situation) to 7 (best situation). The total score is the sum of the score from each question and ranges from 32 to 224 with higher scores representing better quality of life.

  6. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events, and TEAEs Leading to Treatment Discontinuation [ Time Frame: Baseline up to 216 weeks ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Participants must be participating in the SELECTION-LTE study (GS-US-418-3899), currently on 200 mg filgotinib q.d. and fulfill the following conditions:

    • partial Mayo Clinical Score remission over a period of at least 2 consecutive quarterly visits in the SELECTION-LTE study (GS-US-418-3899) prior to and including screening of the present study;
    • free of corticosteroids for at least 12 weeks prior to and including baseline;
    • FCP ≤250 μg/g at last observation;
    • sigmoidoscopy ES of 0 or 1 (local score) at screening.
  • Female participants of childbearing potential must have a negative highly sensitive (serum beta human chorionic gonadotropin) pregnancy test during screening and must agree to continued monthly urine dipstick pregnancy testing during filgotinib treatment.
  • Male participants and female participants of childbearing potential must agree to use highly effective contraception measures as defined in the protocol.
  • Willing to refrain from live attenuated vaccines during the study and for 12 weeks after the last dose of filgotinib in the study.

Key Exclusion Criteria:

  • Any chronic medical condition (including but not limited to, cardiac or pulmonary disease, alcohol, or drug abuse) that, in the opinion of the investigator or sponsor, would make the participant unsuitable for the study or would prevent compliance with the study protocol.
  • Participant has a known hypersensitivity to filgotinib ingredients or history of a significant allergic reaction to filgotinib ingredients as determined by the investigator.
  • Female participant who is pregnant or breastfeeding, or intending to become pregnant or breastfeed, and/or plans to undergo egg donation or egg harvesting for the purpose of current or future fertilization, during the study and until the end of the study.
  • Male participant unwilling to refrain from sperm donation for at least 90 days after the last dose of investigational product (IP).
  • Participant is unable or unwilling to comply with restrictions regarding prior and concomitant medication as described in the protocol.
  • Participant has a positive QuantiFERON® tuberculosis (TB) test at screening or participant has 2 indeterminate QuantiFERON® TB test results who require IP treatment interruption.
  • History of malignancy except for participants who have been successfully treated for nonmelanoma skin cancer or cervical carcinoma in situ.
  • Participant meets discontinuation criteria of the SELECTION-LTE study (GS-US-418-3899).

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05479058


Contacts
Layout table for location contacts
Contact: Galapagos Medical Information +3215342900 medicalinfo@glpg.com

Locations
Show Show 44 study locations
Sponsors and Collaborators
Galapagos NV
Investigators
Layout table for investigator information
Study Director: Galapagos Study Director Galapagos NV
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Galapagos NV
ClinicalTrials.gov Identifier: NCT05479058    
Other Study ID Numbers: GLPG0634-CL-341
2022-000719-30 ( EudraCT Number )
First Posted: July 29, 2022    Key Record Dates
Last Update Posted: March 20, 2023
Last Verified: March 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Colitis
Colitis, Ulcerative
Ulcer
Gastroenteritis
Gastrointestinal Diseases
 Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases